NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating on Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Following Vanda Pharmaceuticals, Inc.’s (NASDAQ: VNDA) first quarter 2017 results, Aegis Capital has reiterated its ‘Buy’ rating and price target of $24 on shares of the company’s stock. The company reported net product sales of $37.4 million in the first quarter of 2017 and reaffirmed its net product sales guidance for 2017 of $165 million to $175 million. The Aegis analyst noted that the company has expanded its sales team for Fanapt®, which should drive growth in the third and fourth quarter of this year. Data from three trials that the analyst cited as catalysts for the year is also expected for the third and fourth quarters.

For more information, visit

About Vanda Pharmaceuticals, Inc.

Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s